DL
Therapeutic Areas
InCarda Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Hospital Cardioversion Program (IV Fixed Dose Combination) | Paroxysmal Atrial Fibrillation and Atrial Flutter | Phase 3 |
| Home Cardioversion Program | Paroxysmal Atrial Fibrillation | Preclinical |
Leadership Team at InCarda Therapeutics
DM
Dr. Myles Greenberg
CEO
CM
Carol Manchester, CPA
CFO
CS
Carlos Schuler, PhD
CTO
NR
Narsi Rangachari, M.Pharm.
CBO